Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CordenPharma Expands API Mfg. Capabilities | Contract Pharma

What are you searching for?

Sign in
Breaking News

CordenPharma Expands API Mfg. Capabilities

Announces commercial oligonucleotide API manufacturing expansion in CordenPharma Colorado

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CordenPharma has expanded operations with new commercial oligonucleotide API manufacturing capabilities at its FDA inspected CordenPharma Colorado facility.

The expansion, which was completed in the first quarter of 2018, will provide cGMP oligonucleotide manufacturing capacity up to 2mol, with a significant increase in total commercial capacity up to 500kg annually, making CordenPharma Colorado one the largest oligonucleotide manufacturing sites worldwide. The facility has not only enhanced capacity, but also put in place a dedicated team of experts with more than 20 years of experience in manufacturing oligonucleotides.

“This expansion will not only provide our customers timely and much needed oligonucleotide API manufacturing services to advance their drug development programs in clinical trials as planned, but also allow them to leverage our regulatory expertise for scale-up and manufacture of commercial products,” said Matthieu Giraud, director, global peptides, oligonucleotides, lipids and carbohydrates platform, CordenPharma. “Drawing upon our strong history in highly potent peptide API manufacturing, CordenPharma Colorado’s engineers implemented an innovative design to ensure low endotoxin / bioburden levels, which are a prerequisite for injectable APIs.”

Brian McCudden, managing director, president and chief executive officer, CordenPharma Boulder and CordenPharma Colorado, said, “The oligonucleotide expansion marks another important milestone in our strategic plan to offer comprehensive development and manufacturing API services. We now offer GMP manufacturing at multiple scales to leverage a seamless technology transfer process from our experienced oligo development team.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics